Phase II Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients With Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) With Standard IM Therapy.
Phase of Trial: Phase II
Latest Information Update: 09 Dec 2014
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 05 Apr 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 08 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.